Lars G. Ekman's Insider Trades & SAST Disclosures
Lars G. Ekman's most recent trade in Prothena Corporation plc was a trade of 15,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 15, 2024.
Add Superstar Alert
Note
This is a custom search result for pattern Lars G. Ekman.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Prothena Corporation plc
|
Lars G. Ekman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.41 per share. | 03 Jan 2023 | 15,834 | 16,077 (0%) | 0% | 6.4 | 101,496 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 15,834 | 0 | - | - | Stock Option (right to buy) | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 56.33 per share. | 03 Jan 2023 | 6,621 | 3,148 (0%) | 0% | 56.3 | 372,970 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 54.15 per share. | 03 Jan 2023 | 3,411 | 12,666 (0%) | 0% | 54.2 | 184,707 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 55.35 per share. | 03 Jan 2023 | 2,897 | 9,769 (0%) | 0% | 55.3 | 160,341 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 58.67 per share. | 03 Jan 2023 | 1,523 | 322 (0%) | 0% | 58.7 | 89,353 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 56.98 per share. | 03 Jan 2023 | 1,303 | 1,845 (0%) | 0% | 57.0 | 74,244 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 60.84 per share. | 03 Jan 2023 | 69 | 243 (0%) | 0% | 60.8 | 4,198 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 59.50 per share. | 03 Jan 2023 | 10 | 312 (0%) | 0% | 59.5 | 595 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.41 per share. | 01 Dec 2022 | 15,834 | 16,077 (0%) | 0% | 6.4 | 101,496 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 15,834 | 15,834 | - | - | Stock Option (right to buy) | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 61.28 per share. | 01 Dec 2022 | 9,813 | 6,264 (0%) | 0% | 61.3 | 601,388 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 62.12 per share. | 01 Dec 2022 | 6,021 | 243 (0%) | 0% | 62.1 | 374,018 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 15,833 | 31,668 | - | - | Stock Option (right to buy) | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.41 per share. | 01 Nov 2022 | 15,833 | 16,076 (0%) | 0% | 6.4 | 101,490 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 62.01 per share. | 01 Nov 2022 | 9,143 | 6,933 (0%) | 0% | 62.0 | 566,953 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 64.26 per share. | 01 Nov 2022 | 3,312 | 1,904 (0%) | 0% | 64.3 | 212,824 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 62.91 per share. | 01 Nov 2022 | 1,717 | 5,216 (0%) | 0% | 62.9 | 108,013 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 64.94 per share. | 01 Nov 2022 | 1,661 | 243 (0%) | 0% | 64.9 | 107,868 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.41 per share. | 03 Oct 2022 | 15,833 | 16,076 (0%) | 0% | 6.4 | 101,490 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 15,833 | 47,501 | - | - | Stock Option (right to buy) | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 62.10 per share. | 03 Oct 2022 | 6,355 | 1,936 (0%) | 0% | 62.1 | 394,677 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 61.07 per share. | 03 Oct 2022 | 4,277 | 8,291 (0%) | 0% | 61.1 | 261,208 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 60.32 per share. | 03 Oct 2022 | 3,508 | 12,568 (0%) | 0% | 60.3 | 211,604 | Ordinary Shares, par value $0.01 per share |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chair of the Board | Sale of securities on an exchange or to another person at price $ 62.96 per share. | 03 Oct 2022 | 1,693 | 243 (0%) | 0% | 63.0 | 106,593 | Ordinary Shares, par value $0.01 per share |
|
Ultragenyx Pharmaceutical ...
|
Lars G. Ekman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 6,245 | 6,245 | - | - | Stock Option (Right to Buy) | |
|
Ultragenyx Pharmaceutical ...
|
Lars G. Ekman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 3,300 | 17,745 (0%) | 0% | 0 | Common Stock | |
|
Ultragenyx Pharmaceutical ...
|
Lars G. Ekman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 4,125 | 4,125 | - | - | Stock Option (Right to Buy) | |
|
Ultragenyx Pharmaceutical ...
|
Lars G. Ekman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 2,145 | 14,445 (0%) | 0% | 0 | Common Stock | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director, Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2021 | 15,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2021 | 15,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2021 | 12,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 9,803 | 9,803 | - | - | Employee Stock Option (Right to Buy) | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 8,426 | 8,426 | - | - | Employee Stock Option (Right to Buy) | |
|
Prothena Corporation plc
|
Lars G. Ekman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 6,315 | 6,315 | - | - | Employee Stock Option (Right to Buy) | |
|
Ultragenyx Pharmaceutical ...
|
Lars G. Ekman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2020 | 4,250 | 4,250 | - | - | Stock Option (Right to Buy) | |
|
Ultragenyx Pharmaceutical ...
|
Lars G. Ekman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2020 | 2,550 | 12,300 (0%) | 0% | 0 | Common Stock | |
|
Prothena Corporation plc
|
Lars G. Ekman | Other, Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2020 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges